Potent synthetic corticosteroid; displays agonist activity at glucocorticoid and progesterone receptors. Exhibits anti-inflammatory effects.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 521.43. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.92 mL||9.59 mL||19.18 mL|
|5 mM||0.38 mL||1.92 mL||3.84 mL|
|10 mM||0.19 mL||0.96 mL||1.92 mL|
|50 mM||0.04 mL||0.19 mL||0.38 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Austin et al (2002) Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur.Respir.J. 20 1386 PMID: 12503693
Ogawa et al (2009) Dissociation of local anti-inflammatory effect and systemic effects of mometasone furoate in mice. Immunopharmacol.Immunotoxicol. 31 601 PMID: 19874229
If you know of a relevant reference for Mometasone furoate, please let us know.
View Related Products by Product Action
Keywords: glucocorticoid receptors agonists corticosteroids anti-inflammatory Glucocorticoid Receptor
Citations for Mometasone furoate
Citations are publications that use Tocris products.
Currently there are no citations for Mometasone furoate. Do you know of a great paper that uses Mometasone furoate from Tocris? If so please let us know.
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.